How does HAPV3's PS Ratio compare to its peers?

HAPV3 is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (2.8x).

How does HAPV3's PS Ratio compare vs other companies in the South American Healthcare Industry?

HAPV3 is good value based on its Price-To-Sales Ratio (0.7x) compared to the South American Healthcare industry average (0.8x).

What is HAPV3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate HAPV3's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of HAPV3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HAPV3 (ARS562) is trading below our estimate of [[fair value]] (ARS1541.57)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Hapvida Participações e Investimentos (BASE:HAPV3) - Stock Price, News & Analysis

HAPV3 Stock Overview

Operates in the health sector in Brazil. More details

HAPV3 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 63.5% below our estimate of its fair value

Earnings are forecast to grow 49.04% per year

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months compared to the AR market

Large one-off items impacting financial results

Hapvida Participações e Investimentos S.A. Competitors

Alignment Healthcare

NasdaqGS:ALHC

US$2.3b

HealthEquity

NasdaqGS:HQY

US$9.0b

Progyny

NasdaqGS:PGNY

US$1.2b

Clover Health Investments

NasdaqGS:CLOV

US$1.7b

Price History & Performance

Summary of all time highs, changes and price drops for Hapvida Participações e Investimentos
Historical stock prices
Current Share Price	R$562.00
52 Week High	R$1,100.00
52 Week Low	R$545.00
Beta	0.72
11 Month Change	-26.25%
3 Month Change	-46.98%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-46.76%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	HAPV3	AR Healthcare	AR Market
7D	-11.8%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how HAPV3 performed against the AR Healthcare industry.

Return vs Market: Insufficient data to determine how HAPV3 performed against the AR Market.

Price Volatility

Is HAPV3's price volatile compared to industry and market?
HAPV3 volatility
HAPV3 Average Weekly Movement	6.7%
Healthcare Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in AR Market	0%
10% least volatile stocks in AR Market	0%

Stable Share Price: HAPV3's share price has been volatile over the past 3 months compared to the AR market.

Volatility Over Time: HAPV3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of AR stocks.

About the Company

Founded	Employees	CEO	Website
1979	n/a	Jorge Fontoura Pinheiro de Lima	ri.hapvida.com.br

Hapvida Participações e Investimentos S.A., together with its subsidiaries, operates in the health sector in Brazil. The company offers medical and dental insurance plans. It also provides medical and paramedical, laboratory, diagnostic, imaging, and ultrasound services, as well as organizes courses, lectures, seminars, and other events.

Hapvida Participações e Investimentos S.A. Fundamentals Summary

How do Hapvida Participações e Investimentos's earnings and revenue compare to its market cap?
HAPV3 fundamental statistics
Market cap	AR$3.91t
Earnings (TTM)	AR$9.21b
Revenue (TTM)	AR$4.97t

404.8x

P/E Ratio

0.7x

P/S Ratio

Is HAPV3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HAPV3 income statement (TTM)
Revenue	R$28.80b
Cost of Revenue	R$24.78b
Gross Profit	R$4.02b
Other Expenses	R$3.97b
Earnings	R$53.32m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.0071
Gross Margin	13.95%
Net Profit Margin	0.19%
Debt/Equity Ratio	22.9%

How did HAPV3 perform over the long term?

See historical performance and comparison